0001209191-21-054118.txt : 20210831
0001209191-21-054118.hdr.sgml : 20210831
20210831172900
ACCESSION NUMBER: 0001209191-21-054118
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210827
FILED AS OF DATE: 20210831
DATE AS OF CHANGE: 20210831
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Kevin
CENTRAL INDEX KEY: 0001776938
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 211227879
MAIL ADDRESS:
STREET 1: C/O BICYCLE THERAPEUTICS LIMITED
STREET 2: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB223AT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-27
0
0001761612
BICYCLE THERAPEUTICS plc
BCYC
0001776938
Lee Kevin
C/O BICYCLE THERAPEUTICS PLC
B900, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE
X0
CB22 3AT
UNITED KINGDOM
1
1
0
0
Chief Executive Officer
Ordinary Shares
2021-08-27
4
M
0
1808
14.00
A
246893
D
Ordinary Shares
2021-08-27
4
S
0
1808
36.02
D
245085
D
Ordinary Shares
2021-08-31
4
M
0
10420
14.00
A
255505
D
Ordinary Shares
2021-08-31
4
S
0
9953
36.23
D
245552
D
Ordinary Shares
2021-08-31
4
S
0
1272
37.08
D
244280
D
Stock Option (right to buy)
14.00
2021-08-27
4
M
0
1808
0.00
D
2029-06-28
Ordinary Shares
1808
339562
D
Stock Option (right to buy)
14.00
2021-08-31
4
M
0
10420
0.00
D
2029-06-28
Ordinary Shares
10420
329142
D
Shares sold pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.86 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.58 inclusive.
This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.
/s/ Lee Kalowski, Attorney-in-Fact
2021-08-31